Juno Therapeutics Financials

Juno Therapeutics Stock Summary

Juno Therapeutics competes with Delek Drilling, Wingstop, BJs Restaurants, Orbit Garant, and Rave Restaurant. Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. Juno Therapeutics, Inc. was founded in 2013 and is headquartered in Seattle, Washington. Juno Therapeutics operates under Biotechnology classification in USA and traded on NASDAQ. It employs 589 people.

Juno Therapeutics Key Financial Ratios

Generally speaking, Juno Therapeutics' financial ratios allow both analysts and investors to convert raw data from Juno Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Juno Therapeutics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Juno Therapeutics reports annually and quarterly.

Juno Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Juno Therapeutics's current stock value. Our valuation model uses many indicators to compare Juno Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Juno Therapeutics competition to find correlations between indicators driving Juno Therapeutics's intrinsic value. More Info.Juno Therapeutics is rated below average in return on equity category among related companies. It is rated below average in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Juno Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Juno Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Juno Therapeutics' earnings, one of the primary drivers of an investment's value.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

If you are still planning to invest in Juno Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Juno Therapeutics' history and understand the potential risks before investing.